INBX — Inhibrx Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 2007919 ·
Last close
$74.18
Market Cap
$1.09B
52W High
$155.29
52W Low
$57.30
ADV30
275,858
Next earnings
2026-11-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 2,000,000 | — | -31,735,000 | -38,733,000 | 220,291,000 | 199,469,000 | 306,167,000 |
| Jun 2026 | 0 | — | -32,149,000 | -36,650,000 | 154,222,000 | 133,344,000 | 207,199,000 |
| Mar 2026 | 0 | — | -30,927,000 | -33,441,000 | 183,967,000 | 161,657,000 | 205,002,000 |
| Dec 2025 | 0 | — | -30,923,000 | -32,834,000 | 146,478,000 | 124,220,000 | 138,485,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-131,889,000
Investing CF
$-7,000
Financing CF
$78,673,000
CapEx
$-31,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-8.88
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-316,278,000
Inventory
—
Receivables
$132,000
ST Investments
—
EBIT TTM
$-122,610,000
Pretax Income TTM
$-138,178,000
Interest Exp TTM
$15,568,000
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$2,000,000
EBITDA
$-123,601,000
Free Cash Flow
$-85,104,872
Enterprise Value
$1,386,707,968
Total Cash
$199,468,992
Total Debt
$276,700,992
Shares Out
14,717,660
Trailing EPS
$-8.88
Book Value
$-5.46
ROE
-1773.6%
ROA
-39.5%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,300,000 | -135,025,000 | -140,055,000 | 146,478,000 | 138,485,000 | 7,993,000 | -129,794,000 |
| Dec 2024 | 200,000 | -331,448,000 | 1,687,572,000 | 180,767,000 | 47,183,000 | 133,584,000 | -194,409,000 |
| Dec 2023 | 1,800,000 | -219,221,000 | -241,361,000 | 307,893,000 | 264,390,000 | 43,503,000 | -193,309,000 |
| Dec 2022 | 1,301,000 | -115,323,000 | -115,325,000 | 16,645,000 | 23,945,000 | -7,300,000 | -90,811,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-138,181,000
OpCashFlow TTM
—
Assets (Latest)
$154,222,000
Forward EPS
$-8.76
Max Pain — expiry 2027-01-15
max pain strike: $65.00 · spot: $69.06 · call oi: 905 · put oi: 282
Expected Move to 2027-01-15:
±$30.55
(44.24%) —
implied range
$38.51 –
$99.61
· ATM straddle on $70.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VOR | Vor Biopharma Inc. | $1.12B | $18.18 | — |
| IMTX | Immatics N.V. | $957.50M | $6.29 | — |
| ODTX | Odyssey Therapeutics, Inc. | $931.07M | $19.37 | — |
| TSHA | Taysha Gene Therapies, Inc. | $1.30B | $4.00 | — |
| NVAX | NOVAVAX INC | $1.31B | $7.96 | — |
News headlines (Yahoo Finance, 1h cache)
Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma
2026-11-17 21:53 · Yahoo
Inhibrx Reports Third Quarter 2026 Financial Results
2026-11-13 21:02 · Yahoo
Inhibrx Biosciences (INBX) Stock Looks Hard To Pin Down At This Price
2026-10-23 10:16 · Yahoo
Are Inhibrx Biosciences' (INBX) Global Data Reveals Reframing Its Late-Stage Pipeline Credibility?
2026-10-14 14:14 · Yahoo
Inhibrx Announces Participation in Upcoming Scientific Conferences
2026-10-13 20:00 · Yahoo
Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
2026-10-02 12:00 · Yahoo
Inhibrx’s Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall?
2026-09-24 17:07 · Yahoo
Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?
2026-09-16 00:29 · Yahoo
Inhibrx Shares Rise After Positive Phase 2 Head and Neck Cancer Data
2026-09-08 12:51 · Yahoo
Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
2026-09-08 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.